# Autolus Therapeutics (AUTL) Stock Analysis: A Biotech with a Massive 407.91% Potential Upside

- Link: https://www.directorstalkinterviews.com/autolus-therapeutics-autl-stock-analysis-a-biotech-with-a-massive-407-91-potential-upside/4121242054
- Published: 2026-02-27T11:35:08+00:00
- Author: Madison Wilson

Autolus Therapeutics plc (NASDAQ: AUTL), a UK-based biotechnology company, is capturing
investor attention with its remarkable potential upside of 407.91%. This ambitious
figure stems from the company’s ongoing efforts in developing innovative T cell 
therapies aimed at treating various cancers and autoimmune diseases.

Operating within the healthcare sector, Autolus Therapeutics distinguishes itself
through its cutting-edge clinical-stage programs. Among its promising candidates
is obecabtagene autoleucel (AUTO1), currently in Phase 1b/2 clinical trials for 
adult acute lymphoblastic leukemia (ALL). Additionally, the company is advancing
AUTO1/22 in pediatric ALL, AUTO4 in peripheral T-cell lymphoma, AUTO6NG in neuroblastoma,
and AUTO8 for multiple myeloma. These programs underscore Autolus’s commitment to
addressing complex medical challenges through cellular therapy.

Currently trading at $1.77, Autolus’s stock has experienced a modest 0.01% change.
Despite its current valuation, the stock has demonstrated a 52-week high of $2.68,
suggesting previous investor confidence in its potential. Analysts are optimistic,
evident from the 11 buy ratings and zero hold or sell ratings. The average target
price stands at $8.99, with estimates ranging from $5.00 to $13.00, reinforcing 
the substantial growth prospects perceived by market experts.

On the technical front, the stock shows a 50-day moving average of $1.59 and a 200-
day moving average of $1.73, with a relative strength index (RSI) of 60.92. The 
MACD indicator at 0.07, along with a signal line of 0.02, suggests a bullish momentum.
These indicators reflect a positive trend, providing a technical foundation for 
the stock’s potential upward trajectory.

However, potential investors should be aware of the financial metrics that illustrate
the inherent risks involved. Autolus currently does not have a trailing P/E ratio,
forward P/E stands at -2.12, and its EPS is -0.83, indicating that the company has
yet to achieve profitability. The return on equity is a concerning -60.56%, and 
the free cash flow is significantly negative at -$267.75 million, highlighting the
financial challenges typical of clinical-stage biotechs.

Despite these financial hurdles, the absence of a dividend yield and payout ratio
is not unexpected, as Autolus is focused on reinvesting in its extensive R&D pipeline
rather than returning profits to shareholders. This strategy is consistent with 
its stage of development and the intense demand for capital in the biotech industry.

For investors with an appetite for risk and a belief in the transformative potential
of T cell therapies, Autolus Therapeutics presents an intriguing opportunity. The
substantial analyst-backed upside potential, combined with innovative product candidates,
positions Autolus as a compelling, albeit speculative, investment within the biotechnology
sector. As with all investments in early-stage biotech companies, due diligence 
and consideration of individual risk tolerance are essential.

Share on:
